As of 2026-05-26, the Intrinsic Value of Solasia Pharma KK (4597.T) is (4,219.71) JPY. This 4597.T valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 27.00 JPY, the upside of Solasia Pharma KK is -15,728.50%.
The range of the Intrinsic Value is (27,523.65) - (2,304.33) JPY
Based on its market price of 27.00 JPY and our intrinsic valuation, Solasia Pharma KK (4597.T) is overvalued by 15,728.50%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (27,523.65) - (2,304.33) | (4,219.71) | -15728.5% |
| DCF (Growth 10y) | (19,514.09) - (247,258.48) | (36,802.60) | -136405.9% |
| DCF (EBITDA 5y) | (1,296.17) - (2,479.57) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (11,366.86) - (23,162.38) | (1,234.50) | -123450.0% |
| Fair Value | -48.07 - -48.07 | -48.07 | -278.05% |
| P/E | (98.50) - (118.68) | (110.11) | -507.8% |
| EV/EBITDA | (39.72) - (39.05) | (50.55) | -287.2% |
| EPV | (39.61) - (55.87) | (47.74) | -276.8% |
| DDM - Stable | (57.84) - (864.75) | (461.30) | -1808.5% |
| DDM - Multi | (1,758.19) - (20,553.72) | (3,247.28) | -12127.0% |
| Market Cap (mil) | 7,382.07 |
| Beta | 1.40 |
| Outstanding shares (mil) | 273.41 |
| Enterprise Value (mil) | 5,899.07 |
| Market risk premium | 6.13% |
| Cost of Equity | 6.03% |
| Cost of Debt | 5.50% |
| WACC | 6.02% |